当前位置:
X-MOL 学术
›
Emerg. Microbes Infect.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Unbiased phage display screening identifies hidden malaria vaccine targets.
Emerging Microbes & Infections ( IF 8.4 ) Pub Date : 2024-11-12 , DOI: 10.1080/22221751.2024.2429617 Marcelo Jacobs-Lorena,Sung-Jae Cha
Emerging Microbes & Infections ( IF 8.4 ) Pub Date : 2024-11-12 , DOI: 10.1080/22221751.2024.2429617 Marcelo Jacobs-Lorena,Sung-Jae Cha
AbstractMalaria is among the deadliest infectious diseases. Over 200 million annual clinical malaria cases are reported and more than half a million people, mostly children, die every year. The most advanced RTS,S/AS01 vaccine based on the P. falciparum circumsporozoite protein (CSP), targets sporozoite liver infection but achieved modest efficacy. To reduce malaria death, novel malaria vaccine development is a high priority. Most malaria vaccine candidates target three infection steps: sporozoite liver infection, merozoite red blood cell (RBC) infection, and mosquito midgut infection. However, only few malaria vaccine candidates target specific parasite-host cell interactions. Our group has implemented the phage peptide-display approach to discover new parasite ligands and host cell receptors. Here we summarize our findings and discuss their potential for the development of novel vaccines.
中文翻译:
无偏倚的噬菌体展示筛选可识别隐藏的疟疾疫苗靶标。
摘要疟疾是最致命的传染病之一。每年报告超过 2 亿例临床疟疾病例,每年有五十多万人死亡,其中大多数是儿童。基于恶性疟原虫环子孢子蛋白 (CSP) 的最先进的 RTS,S/AS01 疫苗针对子孢子肝脏感染,但效果适中。为了减少疟疾死亡,新型疟疾疫苗的开发是重中之重。大多数疟疾候选疫苗针对三个感染步骤:子孢子肝感染、裂殖子红细胞 (RBC) 感染和蚊子中肠感染。然而,只有少数疟疾候选疫苗针对特定的寄生虫-宿主细胞相互作用。我们小组实施了噬菌体肽展示方法来发现新的寄生虫配体和宿主细胞受体。在这里,我们总结了我们的发现并讨论了它们在开发新型疫苗方面的潜力。
更新日期:2024-11-12
中文翻译:
无偏倚的噬菌体展示筛选可识别隐藏的疟疾疫苗靶标。
摘要疟疾是最致命的传染病之一。每年报告超过 2 亿例临床疟疾病例,每年有五十多万人死亡,其中大多数是儿童。基于恶性疟原虫环子孢子蛋白 (CSP) 的最先进的 RTS,S/AS01 疫苗针对子孢子肝脏感染,但效果适中。为了减少疟疾死亡,新型疟疾疫苗的开发是重中之重。大多数疟疾候选疫苗针对三个感染步骤:子孢子肝感染、裂殖子红细胞 (RBC) 感染和蚊子中肠感染。然而,只有少数疟疾候选疫苗针对特定的寄生虫-宿主细胞相互作用。我们小组实施了噬菌体肽展示方法来发现新的寄生虫配体和宿主细胞受体。在这里,我们总结了我们的发现并讨论了它们在开发新型疫苗方面的潜力。